$KZIA The National Cancer Institute sought out this drug from downunder and are paying for the Alliance Trial. Such a decision is made using modern cellular, biochemical, molecular, genetic, protein, metabolite studies, that can be objectively measured and evaluated as to the pathogenic worth of this drug GDC 0084. It is likely or a least probable, the drug works and will get to market. Should that happen the share price, off this micro float size, can increase by 150 times. An issue at the moment for investors is understanding how the drug works. Shutting down errand phosphoinositide 3-kinase (PI3K) cancer enriched pathways, as a potent chemo preventative anti cancer drug, may be seen as novel and unproven. This despite the fact, other PI3K drugs have been approved by the FDA. Now we see here, below, PI3K as integral to cancer cell growth and other disease. Four day long PI3K conference, helps to validate the worth and value of PI3K inhibition. tks.keystonesymposia.org/in...
  • 6
  • 2